S&P/ASX 200 Index (ASX: XJO) shares rose 2.77% and delivered total returns, including dividends, of 7% in FY26.  

Here, we review three fresh buy, hold, and sell calls from expert market analysts.

Weebit Nano Ltd (ASX: WBT)

The Weebit Nano share price soared 414% in FY26 to finish at $8.35 per share.

This was a vastly different performance to many of its peers, which suffered major declines amid a broader tech sector rout. 

Weebit develops advanced semiconductor memory technology.

Mark Elzayed from Investor Pulse reckons there’s more growth ahead for this ASX tech share.

He explains his buy rating on The Bull this week:

Licensing deals with Texas Instruments and onsemi have contributed to company performance. Revenue guidance of $10 million in full year 2026 and a recent capital raising of $102 million fortifies the balance sheet for artificial intelligence and research development.

The shift towards a recurring royalty model generates long term operating leverage.

Momentum and news flow are positive, although the multi year path from licence to royalty income remains the key execution risk.

Metals X Ltd (ASX: MLX)

The Metals X share price ripped 142% to close out FY26 at $1.32.

Elzayed has a hold rating on this ASX materials share.

He explained:

The company is Australia’s largest tin producer. It has a 50 per cent equity interest in the Renison tin operation in Tasmania.

Revenue of $285 million in full year 2025 was up 30 per cent on the prior corresponding period.

However, much of this tin market tightness and consolidation now appears priced into the stock.

The stock is already reflecting a bullish structural tin thesis.

So, in our view, MLX is better suited to holding than buying at these levels.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price fell 29% in FY26 amid a savage healthcare sector downturn. 

However, the stock price of this medical imaging software provider has been recovering strongly since hitting a 52-week low of $107.75 in February.

Pro Medicus shares are up by more than 70% since hitting that floor.

The broader healthcare sector pivoted on 3 June and is also rapidly rising.

Tony Locantro from Alto Capital has a sell recommendation on this ASX 200 healthcare share.

Locantro explained:

The company recently delivered an outstanding first half result in full year 2026. Underlying earnings before interest and tax was up 29.7 per cent and revenue was up 28.4 per cent amid securing more than $A280 million in new contract wins.

Despite these exceptional fundamentals, the company’s premium valuation reflects high market expectations and leaves limited room for disappointment.

While Pro Medicus remains a best-in-class business with strong long term prospects, the current risk-reward balance supports a view to trim holdings at current levels.

The post Buy, hold, sell: Weebit Nano, Metals X, Pro Medicus shares appeared first on The Motley Fool Australia.

More reading

• Up 149% in a year, why this surging ASX 300 tech stock is still a good buy today
• Up 75%, are Pro Medicus shares still a good buy now?
• Why WiseTech shares could rocket 100%
• Where to invest $10,000 in ASX 200 shares in July
• Buy, hold, sell: Pro Medicus, Worley, and ResMed shares

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

These pummeled ASX healthcare shares have both endured brutal share price declines over the past year.

CSL Ltd (ASX: CSL) shares started the week down 0.6% to $122.61. Despite rebounding 13% over the past month, they’re still down around 51% over the past 12 months. Cochlear Ltd (ASX: COH) shares slipped 0.4% on Monday to $119.00, leaving them up 4% over the past month but down an even steeper 61% over the past year.

So, are these former market darlings now genuine buying opportunities or value traps?

CSL: Waiting for earnings to recover

For decades, this $59 billion ASX healthcare share earned its reputation as one of the ASX’s highest-quality companies, driven by global leadership in plasma therapies and a long history of consistent earnings growth.

That reputation has taken a hit. A series of earnings downgrades, leadership changes, and around US$5 billion of non-cash impairments tied largely to the CSL Vifor acquisition have weighed heavily on investor sentiment.

The latest disappointment came in May, when management guided FY26 revenue of approximately US$15.2 billion and NPAT of around US$3.1 billion, both below market expectations. The company also flagged another US$5 billion of non-cash impairments across FY26 and FY27.

Despite that, analysts aren’t entirely bearish. According to TradingView data, 10 of the 18 brokers covering CSL now rate the stock as a hold, while the remaining eight have buy or strong buy recommendations. The average price target sits at $138.88, implying around 13% upside.

UBS remains among the bulls with a $158 target price, arguing much of the bad news surrounding Vifor is already reflected in the share price. The most optimistic analysts see gains of around 60% over the next year.

Cochlear: A temporary stumble?

April marked one of the toughest periods in Cochlear’s history.

The hearing implant leader shocked investors after reporting weaker-than-expected demand across developed markets and disruption to shipments caused by conflict in the Middle East.

Management of the ASX healthcare share slashed FY26 underlying profit guidance from $435 million-$460 million to just $290 million-$330 million, triggering a one-day share price collapse of more than 40%.

Yet the company’s competitive position remains largely intact. Cochlear still controls roughly half the global cochlear implant market, underpinned by decades of product innovation, clinical expertise, and strong relationships with surgeons worldwide.

Its long-term growth opportunity also remains compelling. More than six million people in developed markets are estimated to be eligible for cochlear implants, but only around 3% have received one.

Broker sentiment is cautious. Hold remains the most common TradingView recommendation, with an average target price of $127.14, implying roughly 7% upside.

However, six analysts still rate the shares as a buy or strong buy, with the highest target suggesting upside of around 43%. Two analysts recommend selling, with the lowest target price implying almost 16% downside.

Foolish takeaway

Both ASX healthcare shares remain global leaders with durable competitive advantages, but they are also working through company-specific challenges that have dented investor confidence.

For long-term investors, the sharp share price falls may present an opportunity. However, neither company has yet fully restored market confidence, meaning patience may be required before either regains its former market-leading status.

The post Down 50%+: Are these ASX healthcare shares finally worth buying? appeared first on The Motley Fool Australia.

More reading

• Could CSL shares double from here? Here’s what the experts think
• Here’s why I’d buy and hold CSL and Cochlear shares for 10 years
• Here’s what brokers tip for CSL shares over the next 12 months
• How have CSL shares performed over 10 years?
• Cochlear shares have bounced 16%. Should you buy, hold, or sell now?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It’s never too early to start saving for retirement, and the good news for parents who want to give their children a head start is that, yes, it is possible to set up a superannuation fund for your children.

Superannuation fund selection is the first step

Depending on your child’s age, you might need to shop around to find a fund that allows you to set up accounts for children.

UniSuper, for example, only allows funds to be set up for people aged 15 and above.

Student Super, on the other hand, allows a fund to be set up at any age and charges no administration fees for balances under $1000.

The fund’s Golden Goose Gifting program was specifically set up to make it easy for parents and grandparents to put money into a child’s superannuation account.

Student Super Chief Executive Officer Andrew Moloney says in a video on the fund’s website that Australians generally set up a super fund at about the age of 20, but by setting up a fund early, the benefits of compound interest can accrue for around two decades longer.

In order to set up and contribute into a superannuation fund for a child, it’s necessary to set up a tax file number (TFN) for the child also.

Student Super’s website says, “Once the child’s TFN is added to their account, the parent or guardian will be able to access the details to make a contribution to the child’s super account”.

The magic of compound interest

And the benefits are significant. $1000 contributed when a child is born, compounded over 20 years at 8%, turns into $4661, as calculated on the Moneysmart compound interest calculator.

If $1000 more is added each year, this figure grows to $50,423.

And this isn’t counting the contribution that the Federal Government will make to your child’s super account.

The government makes a co-contribution to superannuation for low-income earners of $500, as long as $1000 in non-concessional (after tax) contributions are made.

As the ATO says:

You don’t need to apply for the super co-contribution. When you lodge your tax return, we will work out if you’re eligible. If your super fund has your tax file number (TFN), we will pay it to your super account automatically.

If $1500 is compounded at 8% over 20 years, the result is $6991; if $1500 is contributed each year for 20 years, the result is a whopping $75,634.

That’s quite the head start, and while super is usually tied up until retirement age, the personal contributions can be withdrawn and used to buy a home under the government’s First Home Super Saver Scheme.

The post How to give your child a $75,000 superannuation head start appeared first on The Motley Fool Australia.

More reading

• Down 50%+: Are these ASX healthcare shares finally worth buying?
• Chemist Warehouse: Are Sigma Healthcare shares a buy, hold, or sell?
• Here are the top 10 ASX 200 shares today
• Are Westpac shares a top buy this week?
• Ophir High Conviction Fund announces FY26 unfranked distribution

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.